Par Pharma Abusing FDA Process To Foil Rivals, Amneal Says
Par Pharmaceutical is looking to sustain huge price hikes for a flagship drug by seeking approval for patent-protected dosing that lacks scientific support and could endanger patients, Amneal Pharmaceuticals told the...To view the full article, register now.
Already a subscriber? Click here to view full article